Thailand Point Of Care Testing Poct Market
Market Size in USD Million
CAGR :
% 
USD
139.18 Million
USD
251.94 Million
2022
2030
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 139.18 Million |
 Market Size (Forecast Year) |
USD 251.94 Million |
 CAGR |
% |
| Major Markets Players |
|
Thailand Point-of-Care Testing (POCT) Market, By Products (Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Diseases Testing Products, Pregnancy and Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drug-of-Abuse Testing Products, Fecal Occult Testing Products, Rapid Coagulation Testing, and other POC Products), Application (Blood Glucose Cardiac Monitoring, Hematology, Coagulation, Whole Blood Analysis, Vital Sign Monitoring, Non-Invasive Spo2 Monitoring, Non-Invasive Pco2 Monitoring, Blood Transfusion, and Others), Platform (Lateral Flow Assays/Immunochromatography Tests, Dipsticks, Molecular Diagnostics, Immunoassays, and Microfluidics), Prescription Mode (Prescription Based Testing and OTC Testing), Testing Type (Immunoassays, Cell-Based Assays, Nucleic Acid Amplification Testing, Clinical Chemistry Assays, and Hematology), End-Users Segment (Hospitals, Clinics, Laboratories, Home Care, Ambulatory Surgical Centers, Others), Distribution Channel (Direct and Retail Pharmacies) - Industry Trends and Forecast to 2030.
Thailand Point-of-Care Testing (POCT) Market Analysis and Size
The point-of-care testing (POCT) is characterized as testing that can be done close to the patient where a medical decision can be made immediately, including the results and monitoring. Point-of-care testing (POCT) is also called with-patient testing. It allows physicians to accurately measure real-time, lab-quality diagnostic results within less than minutes compared to hours. Currently, various products are available that provide rapid and accurate results and help patients better outcomes, which is expected to provide various other opportunities in the point-of-care testing market. However, lack of alignments in the lab results and the high cost of point-of-care testing products are expected to restrain market growth in the forecast period. Presence of major market player is providing an opportunity whereas the lack of trained professionals are challenging the market growth.
Data Bridge Market Research analyses that the Thailand point-of-care testing (POCT) market which was USD 139.18 million in 2022, would reach up to USD 251.94 million by 2030, and is expected to undergo a CAGR of 7.70% during the forecast period. “Glucose Monitoring Products” dominates the product segment of the Thailand point-of-care testing (POCT) market due to higher prevalence of diabetes. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Thailand Point-of-Care Testing (POCT) Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015-2020) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Products (Glucose Monitoring Products, Cardiometabolic Testing Products, Infectious Diseases Testing Products, Pregnancy and Fertility Testing Products, Tumor/Cancer Marker Testing Products, Urinalysis Testing Products, Cholesterol Testing Products, Hematology Testing Products, Drug-of-Abuse Testing Products, Fecal Occult Testing Products, Rapid Coagulation Testing, and other POC Products), Application (Blood Glucose Cardiac Monitoring, Hematology, Coagulation, Whole Blood Analysis, Vital Sign Monitoring, Non-Invasive Spo2 Monitoring, Non-Invasive Pco2 Monitoring, Blood Transfusion, and Others), Platform (Lateral Flow Assays/Immunochromatography Tests, Dipsticks, Molecular Diagnostics, Immunoassays, and Microfluidics), Prescription Mode (Prescription Based Testing and OTC Testing), Testing Type (Immunoassays, Cell-Based Assays, Nucleic Acid Amplification Testing, Clinical Chemistry Assays, and Hematology), End-Users Segment (Hospitals, Clinics, Laboratories, Home Care, Ambulatory Surgical Centers, Others), Distribution Channel (Direct and Retail Pharmacies) |
|
Countries Covered |
Thailand |
|
Market Players Covered |
Bio-Rad Laboratories, Inc. (U.S.), bioMérieux SA (France), Trinity Biotech (Ireland), BD (U.S.), EKF Diagnostics (U.K.), Abbott (U.S.), Quidel Corporation (U.S.), Sienco, Inc. (U.S.), Danaher (U.S.), Chembio Diagnostics Systems, Inc. (U.S.), Nova Biomedical (U.S.), PTS Diagnostics (U.S.), AccuBioTech Co., Ltd (China), Beckman Coulter, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Sekisui Diagnostics (Japan), Instrumentation Laboratory (A Subsidiary Of Werfen) (U.S.), Xiamen Biotime Biotechnology Co., Ltd. (China), FUJIFILM Thailand Ltd. (Thailand) |
|
Market Opportunities |
|
Market Definition
Point of care testing (POCT) refers to medical diagnostic testing performed near or at the patient's location, often outside a traditional laboratory setting. It provides rapid results, typically within minutes, enabling immediate clinical decisions. POCT devices are portable and user-friendly, allowing healthcare professionals to perform tests at the bedside, in clinics, or even at home. Common applications include blood glucose monitoring, infectious disease testing, and pregnancy testing.
Thailand Point-of-Care Testing (POCT) Market Dynamics
Drivers
- Rising Demand for Convenience of Diagnostics
Patients and healthcare providers seek convenient testing options, and POCT devices are often portable, user-friendly, and require minimal sample preparation.
- Rising Demand for Chronic Disease Management
The rising prevalence of chronic diseases, such as diabetes and cardiovascular conditions, drives demand for regular monitoring, which POCT facilitates
Opportunities
- Increased Access to Healthcare
As POCT devices become more widely available and affordable, they can help increase access to healthcare services, especially in rural and underserved areas of Thailand. This can lead to improved healthcare outcomes and reduced healthcare disparities
- Early Disease Detection
POCT devices allow for rapid and convenient testing for various diseases and conditions, including infectious diseases, diabetes, and cardiovascular conditions. The early detection and diagnosis of these conditions can lead to more effective treatment and management, potentially reducing healthcare costs in the long run
Restraints/Challenges
- Regulatory Compliance
Meeting stringent regulatory requirements for POCT devices can be complex and time-consuming, leading to delays in product approvals and market entry
- High Cost
The initial cost of acquiring and implementing POCT devices, and ongoing operational expenses, can be a barrier for healthcare facilities, particularly in resource-limited settings
This point-of-care testing (POCT) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the point-of-care testing (POCT) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
Recent Developments
- In 2020, Beckman Coulter, Inc. had introduced a total laboratory automation solution that sets a new standard for turnaround time. This automation solution services will help in getting good quality results and will improve laboratory operations. This will help the company in setting a new standard of quality services and will thus, help in generating more revenue in the future
- In 2017, Sekisui Diagnostics announced to the distribution of the Mesa Biotech Point of molecular care system for Flu A/Flu B. It helps physicians with rapid infectious disease diagnosis at the point of care with increased sensitivity. Thus, this will help the company in more revenue generation
Thailand Point-of-Care Testing (POCT) Market Scope
Thailand point-of-care testing (POCT) market is segmented on the basis of products, application, platform, prescription mode, testing type, end-users and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Products
- Glucose Monitoring Products
- Cardiometabolic Testing Products
- Infectious Diseases Testing Products
- Pregnancy and Fertility Testing Products
- Tumor/Cancer Marker Testing Products
- Urinalysis Testing Products
- Cholesterol Testing Products
- Hematology Testing Products
- Drug-of-Abuse Testing Products
- Fecal Occult Testing Products
- Rapid Coagulation Testing
- other POC Products
Application
- Blood Glucose Cardiac Monitoring
- Hematology
- Coagulation
- Whole Blood Analysis
- Vital Sign Monitoring
- Non-Invasive Spo2 Monitoring
- Non-Invasive Pco2 Monitoring
- Blood Transfusion
- Others
Platform
- Lateral Flow Assays/Immunochromatography Tests
- Dipsticks
- Molecular Diagnostics
- Immunoassays
- Microfluidics
Prescription Mode
- Prescription Based Testing
- OTC Testing
Testing Type
- Immunoassays
- Cell-Based Assays
- Nucleic Acid Amplification Testing
- Clinical Chemistry Assays
- Hematology
End-Users
- Hospitals
- Clinics
- Laboratories
- Home Care
- Ambulatory Surgical Centers
- Others
Distribution Channel
- Direct
- Retail Pharmacies
Competitive Landscape and Thailand Point-of-Care Testing (POCT) Market Share Analysis
The Thailand point-of-care testing (POCT) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Thailand presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the company’s focus related to Thailand point-of-care testing (POCT) market.
Some of the major players operating in the Thailand point-of-care testing (POCT) market are:
- Bio-Rad Laboratories, Inc. (U.S.)
- bioMérieux SA (France)
- Trinity Biotech (Ireland)
- BD (Becton, Dickinson and Company) (U.S.)
- EKF Diagnostics (U.K.)
- Abbott (U.S.)
- Quidel Corporation (U.S.)
- Sienco, Inc. (U.S.)
- Danaher (U.S.)
- Chembio Diagnostics Systems, Inc. (U.S.)
- Nova Biomedical (U.S.)
- PTS Diagnostics (U.S.)
- AccuBioTech Co., Ltd (China)
- Beckman Coulter, Inc. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Sekisui Diagnostics (Japan)
- Instrumentation Laboratory (A Subsidiary Of Werfen) (U.S.)
- Xiamen Biotime Biotechnology Co., Ltd. (China)
- FUJIFILM Thailand Ltd. (Thailand)
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THAILAND POINT-OF-CARE-TESTING (POCT) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE THAILAND POINT-OF-CARE-TESTING (POCT) SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET : RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 OPPUTUNITY MAP ANALYSIS
13 HEALTHCARE ECONOMY
13.1 HEALTHCARE EXPENDITURE
13.2 CAPITAL EXPENDITURE
13.3 CAPEX TRENDS
13.4 CAPEX ALLOCATION
13.5 FUNDING SOURCES
13.6 INDUSTRY BENCHMARKS
13.7 GDP RATION IN OVERALL GDP
13.8 HEALTHCARE SYSTEM STRUCTURE
13.9 GOVERNMENT POLICIES
13.1 ECONOMIC DEVELOPMENT
14 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY PRODUCT TYPE
14.1 OVERVIEW
14.2 CARDIOMETABOLIC MONITORING PRODUCTS
14.2.1 CARDIAC MARKER TESTING PRODUCTS
14.2.1.1. HSTNL
14.2.1.1.1. MARKET VALUE (USD MILLION)
14.2.1.1.2. MARKET VOLUME (UNITS)
14.2.1.1.3. AVERAGE SELLING PRICE (USD)
14.2.1.2. BNP
14.2.1.2.1. MARKET VALUE (USD MILLION)
14.2.1.2.2. MARKET VOLUME (UNITS)
14.2.1.2.3. AVERAGE SELLING PRICE (USD)
14.2.1.3. D-DIMER
14.2.1.3.1. MARKET VALUE (USD MILLION)
14.2.1.3.2. MARKET VOLUME (UNITS)
14.2.1.3.3. AVERAGE SELLING PRICE (USD)
14.2.1.4. CK-MB
14.2.1.4.1. MARKET VALUE (USD MILLION)
14.2.1.4.2. MARKET VOLUME (UNITS)
14.2.1.4.3. AVERAGE SELLING PRICE (USD)
14.2.1.5. MYOGLOBIN
14.2.1.5.1. MARKET VALUE (USD MILLION)
14.2.1.5.2. MARKET VOLUME (UNITS)
14.2.1.5.3. AVERAGE SELLING PRICE (USD)
14.2.1.6. OTHERS
14.2.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS
14.2.2.1. BLOOD GAS/ELECTROLYTE TESTING CONSUMABLES
14.2.2.1.1. CARTRIDGES
14.2.2.1.1.1 MARKET VALUE (USD MILLION)
14.2.2.1.1.2 MARKET VOLUME (UNITS)
14.2.2.1.1.3 AVERAGE SELLING PRICE (USD)
14.2.2.1.2. REAGENTS
14.2.2.1.2.1 MARKET VALUE (USD MILLION)
14.2.2.1.2.2 MARKET VOLUME (UNITS)
14.2.2.1.2.3 AVERAGE SELLING PRICE (USD)
14.2.2.2. BLOOD GAS/ELECTROLYTE TESTING INSTRUMENTS
14.2.2.2.1. BENCHTOP
14.2.2.2.1.1 BLOOD GAS ANALYZERS
14.2.2.2.1.1.1. MARKET VALUE (USD MILLION)
14.2.2.2.1.1.2. MARKET VOLUME (UNITS)
14.2.2.2.1.1.3. AVERAGE SELLING PRICE (USD)
14.2.2.2.1.2 ELECTROLYTE ANALYZERS
14.2.2.2.1.2.1. MARKET VALUE (USD MILLION)
14.2.2.2.1.2.2. MARKET VOLUME (UNITS)
14.2.2.2.1.2.3. AVERAGE SELLING PRICE (USD)
14.2.2.2.1.3 COMBINED ANALYZERS
14.2.2.2.1.3.1. MARKET VALUE (USD MILLION)
14.2.2.2.1.3.2. MARKET VOLUME (UNITS)
14.2.2.2.1.3.3. AVERAGE SELLING PRICE (USD)
14.2.2.2.2. PORTABLE
14.2.2.2.2.1 BLOOD GAS ANALYZERS
14.2.2.2.2.1.1. MARKET VALUE (USD MILLION)
14.2.2.2.2.1.2. MARKET VOLUME (UNITS)
14.2.2.2.2.1.3. AVERAGE SELLING PRICE (USD)
14.2.2.2.2.2 ELECTROLYTE ANALYZERS
14.2.2.2.2.2.1. MARKET VALUE (USD MILLION)
14.2.2.2.2.2.2. MARKET VOLUME (UNITS)
14.2.2.2.2.2.3. AVERAGE SELLING PRICE (USD)
14.2.2.2.2.3 COMBINED ANALYZERS
14.2.2.2.2.3.1. MARKET VALUE (USD MILLION)
14.2.2.2.2.3.2. MARKET VOLUME (UNITS)
14.2.2.2.2.3.3. AVERAGE SELLING PRICE (USD)
14.2.3 HBA1C TESTING PRODUCTS
14.2.3.1. HBA1C TESTING INSTRUMENTS
14.2.3.1.1. MARKET VALUE (USD MILLION)
14.2.3.1.2. MARKET VOLUME (UNITS)
14.2.3.1.3. AVERAGE SELLING PRICE (USD)
14.2.3.2. HBA1C TESTING CONSUMABLES
14.2.3.2.1. MARKET VALUE (USD MILLION)
14.2.3.2.2. MARKET VOLUME (UNITS)
14.2.3.2.3. AVERAGE SELLING PRICE (USD)
14.2.4 POC ANALYSER
14.2.4.1. MARKET VALUE (USD MILLION)
14.2.4.2. MARKET VOLUME (UNITS)
14.2.4.3. AVERAGE SELLING PRICE (USD)
14.2.5 ECG DEVICE
14.2.5.1. RESTING ECG DEVICES
14.2.5.1.1. MARKET VALUE (USD MILLION)
14.2.5.1.2. MARKET VOLUME (UNITS)
14.2.5.1.3. AVERAGE SELLING PRICE (USD)
14.2.5.2. STRESS ECG DEVICES
14.2.5.2.1. MARKET VALUE (USD MILLION)
14.2.5.2.2. MARKET VOLUME (UNITS)
14.2.5.2.3. AVERAGE SELLING PRICE (USD)
14.2.5.3. HOLTER MONITORS
14.2.5.3.1. MARKET VALUE (USD MILLION)
14.2.5.3.2. MARKET VOLUME (UNITS)
14.2.5.3.3. AVERAGE SELLING PRICE (USD)
14.2.6 OTHERS
14.3 GLUCOSE MONITORING PRODUCTS
14.3.1 STRIPS
14.3.1.1. MARKET VALUE (USD MILLION)
14.3.1.2. MARKET VOLUME (UNITS)
14.3.1.3. AVERAGE SELLING PRICE (USD)
14.3.2 METERS
14.3.2.1. MARKET VALUE (USD MILLION)
14.3.2.2. MARKET VOLUME (UNITS)
14.3.2.3. AVERAGE SELLING PRICE (USD)
14.3.3 LANCETS & LANCING DEVICES
14.3.3.1. MARKET VALUE (USD MILLION)
14.3.3.2. MARKET VOLUME (UNITS)
14.3.3.3. AVERAGE SELLING PRICE (USD)
14.4 INFECTIOUS DISEASE TESTING PRODUCTS
14.4.1 INFLUENZA TESTING PRODUCTS
14.4.1.1. TRADITIONAL DIAGNOSTIC TEST
14.4.1.1.1. RAPID INFLUENZA DIAGNOSTIC TEST (RIDT)
14.4.1.1.1.1 MARKET VALUE (USD MILLION)
14.4.1.1.1.2 MARKET VOLUME (UNITS)
14.4.1.1.1.3 AVERAGE SELLING PRICE (USD)
14.4.1.1.2. DIRECT FLUORESCENT ANTIBODY TEST (DFAT)
14.4.1.1.2.1 MARKET VALUE (USD MILLION)
14.4.1.1.2.2 MARKET VOLUME (UNITS)
14.4.1.1.2.3 AVERAGE SELLING PRICE (USD)
14.4.1.1.3. VIRAL CULTURE
14.4.1.1.3.1 MARKET VALUE (USD MILLION)
14.4.1.1.3.2 MARKET VOLUME (UNITS)
14.4.1.1.3.3 AVERAGE SELLING PRICE (USD)
14.4.1.1.4. SEROLOGICAL ASSAY
14.4.1.1.4.1 MARKET VALUE (USD MILLION)
14.4.1.1.4.2 MARKET VOLUME (UNITS)
14.4.1.1.4.3 AVERAGE SELLING PRICE (USD)
14.4.1.2. MOLECULAR DIAGNOSTIC ASSAY
14.4.1.2.1. RT-PCR
14.4.1.2.1.1 MARKET VALUE (USD MILLION)
14.4.1.2.1.2 MARKET VOLUME (UNITS)
14.4.1.2.1.3 AVERAGE SELLING PRICE (USD)
14.4.1.2.2. LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAY (LAMP)
14.4.1.2.2.1 MARKET VALUE (USD MILLION)
14.4.1.2.2.2 MARKET VOLUME (UNITS)
14.4.1.2.2.3 AVERAGE SELLING PRICE (USD)
14.4.1.2.3. NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION TEST (NASBAT)
14.4.1.2.3.1 MARKET VALUE (USD MILLION)
14.4.1.2.3.2 MARKET VOLUME (UNITS)
14.4.1.2.3.3 AVERAGE SELLING PRICE (USD)
14.4.1.2.4. SIMPLE AMPLIFICATION-BASED ASSAY (SAMBA)
14.4.1.2.4.1 MARKET VALUE (USD MILLION)
14.4.1.2.4.2 MARKET VOLUME (UNITS)
14.4.1.2.4.3 AVERAGE SELLING PRICE (USD)
14.4.1.2.5. OTHERS
14.4.2 HIV TESTING PRODUCTS
14.4.2.1. TESTING EQUIPMENT
14.4.2.1.1. MARKET VALUE (USD MILLION)
14.4.2.1.2. MARKET VOLUME (UNITS)
14.4.2.1.3. AVERAGE SELLING PRICE (USD)
14.4.2.2. TESTING REAGENT
14.4.2.2.1. MARKET VALUE (USD MILLION)
14.4.2.2.2. MARKET VOLUME (UNITS)
14.4.2.2.3. AVERAGE SELLING PRICE (USD)
14.4.3 HEPATITIS C TESTING PRODUCTS
14.4.3.1. HCV ANTIBODY TESTS
14.4.3.1.1. MARKET VALUE (USD MILLION)
14.4.3.1.2. MARKET VOLUME (UNITS)
14.4.3.1.3. AVERAGE SELLING PRICE (USD)
14.4.3.2. HCV VIRAL LOAD TESTS
14.4.3.2.1. MARKET VALUE (USD MILLION)
14.4.3.2.2. MARKET VOLUME (UNITS)
14.4.3.2.3. AVERAGE SELLING PRICE (USD)
14.4.3.3. OTHER TESTS
14.4.4 SEXUALLY TRANSMITTED DISEASE (STD) TESTING
14.4.4.1. NAAT-BASED SYSTEMS
14.4.4.1.1. MARKET VALUE (USD MILLION)
14.4.4.1.2. MARKET VOLUME (UNITS)
14.4.4.1.3. AVERAGE SELLING PRICE (USD)
14.4.4.2. NON–NAAT-BASED SYSTEMS
14.4.4.2.1. MARKET VALUE (USD MILLION)
14.4.4.2.2. MARKET VOLUME (UNITS)
14.4.4.2.3. AVERAGE SELLING PRICE (USD)
14.4.5 HEALTHCARE-ASSOCIATED INFECTION (HAI) TESTING
14.4.5.1. MARKET VALUE (USD MILLION)
14.4.5.2. MARKET VOLUME (UNITS)
14.4.5.3. AVERAGE SELLING PRICE (USD)
14.4.6 RESPIRATORY INFECTION TESTING PRODUCTS
14.4.6.1. MARKET VALUE (USD MILLION)
14.4.6.2. MARKET VOLUME (UNITS)
14.4.6.3. AVERAGE SELLING PRICE (USD)
14.4.7 TROPICAL DISEASE TESTING PRODUCTS
14.4.7.1. MARKET VALUE (USD MILLION)
14.4.7.2. MARKET VOLUME (UNITS)
14.4.7.3. AVERAGE SELLING PRICE (USD)
14.4.8 COVID-19
14.4.8.1. MARKET VALUE (USD MILLION)
14.4.8.2. MARKET VOLUME (UNITS)
14.4.8.3. AVERAGE SELLING PRICE (USD)
14.4.9 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
14.5 COAGULATION MONITORING PRODUCTS
14.5.1 ANTICOAGULATION MONITORING DEVICES
14.5.1.1. PROTHROMBIN TIME/INTERNATIONAL NORMALIZED RATIO (PT-INR) TESTING DEVICES
14.5.1.1.1. MARKET VALUE (USD MILLION)
14.5.1.1.2. MARKET VOLUME (UNITS)
14.5.1.1.3. AVERAGE SELLING PRICE (USD)
14.5.1.2. ACTIVATED CLOTTING TIME (ACT)
14.5.1.2.1. MARKET VALUE (USD MILLION)
14.5.1.2.2. MARKET VOLUME (UNITS)
14.5.1.2.3. AVERAGE SELLING PRICE (USD)
14.5.1.3. ACTIVATED PARTIAL THROMBOPLASTIN TIME (APPT)
14.5.1.3.1. MARKET VALUE (USD MILLION)
14.5.1.3.2. MARKET VOLUME (UNITS)
14.5.1.3.3. AVERAGE SELLING PRICE (USD)
14.5.2 PLATELET FUNCTION MONITORING DEVICES
14.5.2.1. MARKET VALUE (USD MILLION)
14.5.2.2. MARKET VOLUME (UNITS)
14.5.2.3. AVERAGE SELLING PRICE (USD)
14.5.3 VISCOELASTIC COAGULATION MONITORING DEVICES
14.5.3.1. THROMBOELASTOGRAPHY (TEG)
14.5.3.1.1. MARKET VALUE (USD MILLION)
14.5.3.1.2. MARKET VOLUME (UNITS)
14.5.3.1.3. AVERAGE SELLING PRICE (USD)
14.5.3.2. ROTATIONAL THROMBOELASTOMETRY (ROTEM)
14.5.3.2.1. MARKET VALUE (USD MILLION)
14.5.3.2.2. MARKET VOLUME (UNITS)
14.5.3.2.3. AVERAGE SELLING PRICE (USD)
14.5.4 OTHERS
14.6 PREGNANCY & FERTILITY TESTING PRODUCTS
14.6.1 PREGNANCY TESTING PRODUCTS
14.6.1.1. PREGNANCY TESTING , BY PRODUCT TYPE
14.6.1.1.1. STRIPS/ DIP STICKS AND CARDS
14.6.1.1.1.1 MARKET VALUE (USD MILLION)
14.6.1.1.1.2 MARKET VOLUME (UNITS)
14.6.1.1.1.3 AVERAGE SELLING PRICE (USD)
14.6.1.1.2. MID STREAM DEVICES
14.6.1.1.2.1 MARKET VALUE (USD MILLION)
14.6.1.1.2.2 MARKET VOLUME (UNITS)
14.6.1.1.2.3 AVERAGE SELLING PRICE (USD)
14.6.1.1.3. CASSETTES
14.6.1.1.3.1 MARKET VALUE (USD MILLION)
14.6.1.1.3.2 MARKET VOLUME (UNITS)
14.6.1.1.3.3 AVERAGE SELLING PRICE (USD)
14.6.1.1.4. DIGITAL DEVICES
14.6.1.1.4.1 MARKET VALUE (USD MILLION)
14.6.1.1.4.2 MARKET VOLUME (UNITS)
14.6.1.1.4.3 AVERAGE SELLING PRICE (USD)
14.6.1.1.5. LINE-INDICATOR DEVICES
14.6.1.1.5.1 MARKET VALUE (USD MILLION)
14.6.1.1.5.2 MARKET VOLUME (UNITS)
14.6.1.1.5.3 AVERAGE SELLING PRICE (USD)
14.6.1.2. PREGNANCY TESTING, BY TEST TYPE
14.6.1.2.1. FSH URINE TEST
14.6.1.2.1.1 MARKET VALUE (USD MILLION)
14.6.1.2.1.2 MARKET VOLUME (UNITS)
14.6.1.2.1.3 AVERAGE SELLING PRICE (USD)
14.6.1.2.2. LUTEINIZING HORMONE (LH) URINE TEST
14.6.1.2.2.1 MARKET VALUE (USD MILLION)
14.6.1.2.2.2 MARKET VOLUME (UNITS)
14.6.1.2.2.3 AVERAGE SELLING PRICE (USD)
14.6.1.2.3. HUMAN CHORIONIC GONADOTROPIN (HCG) BLOOD/SERUM TEST
14.6.1.2.3.1 MARKET VALUE (USD MILLION)
14.6.1.2.3.2 MARKET VOLUME (UNITS)
14.6.1.2.3.3 AVERAGE SELLING PRICE (USD)
14.6.1.2.4. HCG URINE TEST
14.6.1.2.4.1 MARKET VALUE (USD MILLION)
14.6.1.2.4.2 MARKET VOLUME (UNITS)
14.6.1.2.4.3 AVERAGE SELLING PRICE (USD)
14.6.2 FERTILITY TESTING PRODUCTS
14.6.2.1. HUMAN CHORIONIC GONADOTROPIN (HCG) URINE TEST
14.6.2.1.1. MARKET VALUE (USD MILLION)
14.6.2.1.2. MARKET VOLUME (UNITS)
14.6.2.1.3. AVERAGE SELLING PRICE (USD)
14.6.2.2. FSH URINE TEST
14.6.2.2.1. MARKET VALUE (USD MILLION)
14.6.2.2.2. MARKET VOLUME (UNITS)
14.6.2.2.3. AVERAGE SELLING PRICE (USD)
14.6.2.3. HUMAN CHORIONIC GONADOTROPIN (HCG) BLOOD TEST
14.6.2.3.1. MARKET VALUE (USD MILLION)
14.6.2.3.2. MARKET VOLUME (UNITS)
14.6.2.3.3. AVERAGE SELLING PRICE (USD)
14.6.2.4. LUTEINIZING HORMONE (LH) URINE TEST
14.6.2.4.1. MARKET VALUE (USD MILLION)
14.6.2.4.2. MARKET VOLUME (UNITS)
14.6.2.4.3. AVERAGE SELLING PRICE (USD)
14.7 TUMOR/CANCER MARKER TESTING PRODUCTS
14.7.1 MARKET VALUE (USD MILLION)
14.7.2 MARKET VOLUME (UNITS)
14.7.3 AVERAGE SELLING PRICE (USD)
14.8 URINALYSIS TESTING PRODUCTS
14.8.1 POC URINE STRIP SELF-TESTING
14.8.1.1. MARKET VALUE (USD MILLION)
14.8.1.2. MARKET VOLUME (UNITS)
14.8.1.3. AVERAGE SELLING PRICE (USD)
14.8.2 POC URINE TEST STRIP PROFESSIONAL TESTING
14.8.2.1. MARKET VALUE (USD MILLION)
14.8.2.2. MARKET VOLUME (UNITS)
14.8.2.3. AVERAGE SELLING PRICE (USD)
14.9 CHOLESTEROL TESTING PRODUCTS
14.9.1 INSTRUMENTS
14.9.1.1. TABLE-TOP ANALYZERS
14.9.1.1.1. MARKET VALUE (USD MILLION)
14.9.1.1.2. MARKET VOLUME (UNITS)
14.9.1.1.3. AVERAGE SELLING PRICE (USD)
14.9.1.2. HAND-HELD ANALYZERS
14.9.1.2.1. MARKET VALUE (USD MILLION)
14.9.1.2.2. MARKET VOLUME (UNITS)
14.9.1.2.3. AVERAGE SELLING PRICE (USD)
14.9.2 TESTING KITS
14.9.2.1. MARKET VALUE (USD MILLION)
14.9.2.2. MARKET VOLUME (UNITS)
14.9.2.3. AVERAGE SELLING PRICE (USD)
14.1 HEMATOLOGY TESTING PRODUCTS
14.10.1 MARKET VALUE (USD MILLION)
14.10.2 MARKET VOLUME (UNITS)
14.10.3 AVERAGE SELLING PRICE (USD)
14.11 DRUGS-OF-ABUSE (DOA) TESTING PRODUCTS
14.11.1 DOA ANALYSERS
14.11.1.1. IMMUNOASSAYS
14.11.1.1.1. MARKET VALUE (USD MILLION)
14.11.1.1.2. MARKET VOLUME (UNITS)
14.11.1.1.3. AVERAGE SELLING PRICE (USD)
14.11.1.2. CHROMATOGRAPHIC DEVICES
14.11.1.2.1. MARKET VALUE (USD MILLION)
14.11.1.2.2. MARKET VOLUME (UNITS)
14.11.1.2.3. AVERAGE SELLING PRICE (USD)
14.11.1.3. BREATH ANALYSERS
14.11.1.3.1. MARKET VALUE (USD MILLION)
14.11.1.3.2. MARKET VOLUME (UNITS)
14.11.1.3.3. AVERAGE SELLING PRICE (USD)
14.11.2 RAPID TESTING DEVICES
14.11.2.1. URINE TESTING DEVICES
14.11.2.1.1. MARKET VALUE (USD MILLION)
14.11.2.1.2. MARKET VOLUME (UNITS)
14.11.2.1.3. AVERAGE SELLING PRICE (USD)
14.11.2.2. ORAL FLUID TESTING DEVICES
14.11.2.2.1. MARKET VALUE (USD MILLION)
14.11.2.2.2. MARKET VOLUME (UNITS)
14.11.2.2.3. AVERAGE SELLING PRICE (USD)
14.11.3 OTHERS
14.12 FECAL OCCULT TESTING PRODUCTS
14.12.1 GUAIAC FOB STOOL TEST
14.12.1.1. MARKET VALUE (USD MILLION)
14.12.1.2. MARKET VOLUME (UNITS)
14.12.1.3. AVERAGE SELLING PRICE (USD)
14.12.2 IMMUNO-FOB AGGLUTINATION TEST
14.12.2.1. MARKET VALUE (USD MILLION)
14.12.2.2. MARKET VOLUME (UNITS)
14.12.2.3. AVERAGE SELLING PRICE (USD)
14.12.3 LATERAL FLOW IMMUNO-FOB TEST
14.12.3.1. MARKET VALUE (USD MILLION)
14.12.3.2. MARKET VOLUME (UNITS)
14.12.3.3. AVERAGE SELLING PRICE (USD)
14.12.4 IMMUNO-FOB ELISA TEST
14.12.4.1. MARKET VALUE (USD MILLION)
14.12.4.2. MARKET VOLUME (UNITS)
14.12.4.3. AVERAGE SELLING PRICE (USD)
14.13 OTHER POC PRODUCTS
15 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY APPLICATION
15.1 OVERVIEW
15.2 BLOOD TRANSFUSION
15.3 CARDIAC MONITORING
15.4 COAGULATION
15.5 BLOOD GLUCOSE
15.6 HAEMATOLOGY
15.7 NON- INVASIVE SPO2 MONITORING
15.8 NON- INVASIVE PCO2 MONITORING
15.9 WHOLE BLOOD ANALYSIS
15.1 VITAL SIGN MONITORING
15.11 OTHERS
16 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY PLATFORM
16.1 OVERVIEW
16.2 LATERAL FLOW ASSAYS
16.3 IMMUNOCHROMATOGRAPHY TESTS
16.4 DIPSTICKS
16.5 MICROFLUIDICS
16.6 MOLECULAR DIAGNOSTICS
16.7 IMMUNOASSAYS
16.8 CLINICAL CHEMISTRY ASSAYS
16.9 HEMATOLOGY
16.1 OTHERS
17 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY PRESCRIPTION MODE
17.1 OVERVIEW
17.2 PRESCRIPTION-BASED TESTING
17.3 OTC TESTING
18 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY TESTING LOCATION
18.1 OVERVIEW
18.2 LABORATORY BASED POINT-OF-CARE-TESTING (POCT)
18.3 AT-HOME POINT-OF-CARE-TESTING (POCT)
19 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY END USER
19.1 OVERVIEW
19.2 HOSPITAL
19.2.1 PRIVATE
19.2.1.1. TIER 1
19.2.1.2. TIER 2
19.2.1.3. TIER 3
19.2.2 PUBLIC
19.2.2.1. TIER 1
19.2.2.2. TIER 2
19.2.2.3. TIER 3
19.3 CLINICS
19.4 LABORATORIES
19.5 PATHOLOGY LABS
19.6 DIAGNOSTIC CENTER
19.7 HOME CARE
19.8 AMBULATORY SURGERY CENTERS
19.9 ELDERLY CARE CENTERS
19.1 OTHERS
20 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY DISTRIBUTION CHANNEL
20.1 OVERVIEW
20.2 DIRECT TENDER
20.3 RETAIL SALES
20.4 ONLINE SALES
20.5 OTHERS
21 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , SWOT AND DBMR ANALYSIS
22 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , COMPANY LANDSCAPE
22.1 COMPANY SHARE ANALYSIS: THAILAND
22.2 MERGERS & ACQUISITIONS
22.3 NEW PRODUCT DEVELOPMENT & APPROVALS
22.4 EXPANSIONS
22.5 REGULATORY CHANGES
22.6 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
23 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , BY REGION
Thailand Point-of-Care-Testing (POCT) Market , (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
23.1 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
24 THAILAND POINT-OF-CARE-TESTING (POCT) MARKET , COMPANY PROFILE
24.1 F. HOFFMANN-LA ROCHE LTD
24.1.1 COMPANY OVERVIEW
24.1.2 REVENUE ANALYSIS
24.1.3 GEOGRAPHIC PRESENCE
24.1.4 PRODUCT PORTFOLIO
24.1.5 RECENT DEVELOPMENTS
24.2 SIEMENS HEALTHCARE GMBH
24.2.1 COMPANY OVERVIEW
24.2.2 REVENUE ANALYSIS
24.2.3 GEOGRAPHIC PRESENCE
24.2.4 PRODUCT PORTFOLIO
24.2.5 RECENT DEVELOPMENTS
24.3 ABBOTT
24.3.1 COMPANY OVERVIEW
24.3.2 REVENUE ANALYSIS
24.3.3 GEOGRAPHIC PRESENCE
24.3.4 PRODUCT PORTFOLIO
24.3.5 RECENT DEVELOPMENTS
24.4 BIOMÉRIEUX
24.4.1 COMPANY OVERVIEW
24.4.2 REVENUE ANALYSIS
24.4.3 GEOGRAPHIC PRESENCE
24.4.4 PRODUCT PORTFOLIO
24.4.5 RECENT DEVELOPMENTS
24.5 ACON LABORATORIES, INC.
24.5.1 COMPANY OVERVIEW
24.5.2 REVENUE ANALYSIS
24.5.3 GEOGRAPHIC PRESENCE
24.5.4 PRODUCT PORTFOLIO
24.5.5 RECENT DEVELOPMENTS
24.6 BIO-RAD LABORATORIES, INC
24.6.1 COMPANY OVERVIEW
24.6.2 REVENUE ANALYSIS
24.6.3 GEOGRAPHIC PRESENCE
24.6.4 PRODUCT PORTFOLIO
24.6.5 RECENT DEVELOPMENTS
24.7 WERFEN
24.7.1 COMPANY OVERVIEW
24.7.2 REVENUE ANALYSIS
24.7.3 GEOGRAPHIC PRESENCE
24.7.4 PRODUCT PORTFOLIO
24.7.5 RECENT DEVELOPMENTS
24.8 NOVA BIOMEDICAL
24.8.1 COMPANY OVERVIEW
24.8.2 REVENUE ANALYSIS
24.8.3 GEOGRAPHIC PRESENCE
24.8.4 PRODUCT PORTFOLIO
24.8.5 RECENT DEVELOPMENTS
24.9 PTS DIAGNOSTICS
24.9.1 COMPANY OVERVIEW
24.9.2 REVENUE ANALYSIS
24.9.3 GEOGRAPHIC PRESENCE
24.9.4 PRODUCT PORTFOLIO
24.9.5 RECENT DEVELOPMENTS
24.1 SEKISUI DIAGNOSTICS
24.10.1 COMPANY OVERVIEW
24.10.2 REVENUE ANALYSIS
24.10.3 GEOGRAPHIC PRESENCE
24.10.4 PRODUCT PORTFOLIO
24.10.5 RECENT DEVELOPMENTS
24.11 TRINITY BIOTECH
24.11.1 COMPANY OVERVIEW
24.11.2 REVENUE ANALYSIS
24.11.3 GEOGRAPHIC PRESENCE
24.11.4 PRODUCT PORTFOLIO
24.11.5 RECENT DEVELOPMENTS
24.12 DANAHER
24.12.1 COMPANY OVERVIEW
24.12.2 REVENUE ANALYSIS
24.12.3 GEOGRAPHIC PRESENCE
24.12.4 PRODUCT PORTFOLIO
24.12.5 RECENT DEVELOPMENTS
24.13 THERMO FISHER SCIENTIFIC INC
24.13.1 COMPANY OVERVIEW
24.13.2 REVENUE ANALYSIS
24.13.3 GEOGRAPHIC PRESENCE
24.13.4 PRODUCT PORTFOLIO
24.13.5 RECENT DEVELOPMENTS
24.14 MERIDIAN DIAGNOSTICS
24.14.1 COMPANY OVERVIEW
24.14.2 REVENUE ANALYSIS
24.14.3 GEOGRAPHIC PRESENCE
24.14.4 PRODUCT PORTFOLIO
24.14.5 RECENT DEVELOPMENTS
24.15 BD
24.15.1 COMPANY OVERVIEW
24.15.2 REVENUE ANALYSIS
24.15.3 GEOGRAPHIC PRESENCE
24.15.4 PRODUCT PORTFOLIO
24.15.5 RECENT DEVELOPMENTS
24.16 SYSMEX (THAILAND) CO., LTD
24.16.1 COMPANY OVERVIEW
24.16.2 REVENUE ANALYSIS
24.16.3 GEOGRAPHIC PRESENCE
24.16.4 PRODUCT PORTFOLIO
24.16.5 RECENT DEVELOPMENTS
24.17 FUJIFILM THAILAND LTD.
24.17.1 COMPANY OVERVIEW
24.17.2 REVENUE ANALYSIS
24.17.3 GEOGRAPHIC PRESENCE
24.17.4 PRODUCT PORTFOLIO
24.17.5 RECENT DEVELOPMENTS
25 RELATED REPORTS
26 CONCLUSION
27 QUESTIONNAIRE
28 ABOUT DATA BRIDGE MARKET RESEARCH
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
